Dr. Wolf Discusses the Videssa Breast Blood Test

Judith K. Wolf, MD
Published: Thursday, Jan 19, 2017



Judith K. Wolf, MD, chief medical officer of Provista Diagnostics, discusses the capabilities of the blood-based diagnostic test Videssa Breast.

Diagnosing breast cancer in women with abnormalities, such as dense breast tissue, is difficult for clinicians, says Wolf. During a mammogram, images can be obscured or unclear in women with dense breasts, making breast cancer detection challenging.

Videssa Breast, a blood-based test from Provista, is being used to test to detect breast cancer in women earlier than traditional detection methods, especially in women with dense breasts. Through its combination of serum protein biomarkers and tumor-associated autoantibodies, it creates a unique protein signature that can be used to detect breast cancer and aid in the decision to seek further testing.
 


Judith K. Wolf, MD, chief medical officer of Provista Diagnostics, discusses the capabilities of the blood-based diagnostic test Videssa Breast.

Diagnosing breast cancer in women with abnormalities, such as dense breast tissue, is difficult for clinicians, says Wolf. During a mammogram, images can be obscured or unclear in women with dense breasts, making breast cancer detection challenging.

Videssa Breast, a blood-based test from Provista, is being used to test to detect breast cancer in women earlier than traditional detection methods, especially in women with dense breasts. Through its combination of serum protein biomarkers and tumor-associated autoantibodies, it creates a unique protein signature that can be used to detect breast cancer and aid in the decision to seek further testing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x